A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example.
Data on absolute risks of outcomes and patterns of drug use in cost-effectiveness analyses are often based on randomised clinical trials (RCTs). The objective of this study was to evaluate the external validity of published cost-effectiveness studies by comparing the data used in these studies (typi...
Main Authors: | Tjeerd-Pieter van Staa, Hubert G Leufkens, Bill Zhang, Liam Smeeth |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-12-01
|
Series: | PLoS Medicine |
Online Access: | http://europepmc.org/articles/PMC2779340?pdf=render |
Similar Items
-
Correction: Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data
by: Arlene M. Gallagher, et al.
Published: (2013-01-01) -
Correction: Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data.
by: Arlene M. Gallagher, et al.
Published: (2013-01-01) -
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
by: Arlene M Gallagher, et al.
Published: (2011-01-01) -
Randomised Evaluations of Accepted Choices in Treatment (REACT) trials: large-scale pragmatic trials within databases of routinely collected electronic healthcare records
by: van Staa Tjeerd-Pieter, et al.
Published: (2011-12-01) -
Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?
by: Tjeerd-Pieter van Staa, et al.
Published: (2014-01-01)